JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.

ACS Med Chem Lett February 11, 2025 DOI: 10.1021/acsmedchemlett.5c00066 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed

Abstract

Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.

Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders. ACS Med Chem Lett March 13, 2025
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses. ACS Med Chem Lett January 23, 2025
Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating Disorders. ACS Med Chem Lett August 14, 2025
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders. ACS Med Chem Lett April 27, 2026
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders. ACS Med Chem Lett February 13, 2025